amprenavir (agenerase) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Amprenavir is an inhibitor of HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. Amprenavir-containing combination regimens have shown virological efficacy, and have generally been well tolerated, in patients with HIV infection (primarily treatment-naive or protease inhibitor-naive). Fosamprenavir (GW433908, Lexiva, Telzir) is an oral prodrug of amprenavir, with a reduced daily pill burden. The use of protease inhibitors has also been associated with dyslipidemia and an increased risk of cardiovascular disease. Amprenavir activates Pregnane X receptor to mediate dyslipidemia.   NCATS

Chemistry

  • SMILES: CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3
  • InChIKey: YMARZQAQMVYCKC-OEMFJLHTSA-N
  • Mol. Mass: 505.627
  • ALogP: 2.4
  • ChEMBL Molecule:
    amprenavir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

141w94 | 141 w94 | (3s)-tetrahydro-3-furanyl ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate | agenerase | amprenavir | amprénavir | amprenavirum | angenerase | glaxosmithkline brand of amprenavir | glaxo wellcome brand of amprenavir | kvx-478 | samprenavir | tetrahydro-3-furyl n-(3-(4-amino-n-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate | vertex vx478 | vx 478 | vx-478

Organizations (21)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

HIV Infections (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Cardiovascular Diseases (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue